Search research articles
Contact Us
Filters
Showing results (21-30 of 48) with videos related to
Page
of 5
Sort By:
Frontiers in Immunology
|
March 27, 2026
Immuno-radiotherapy enhances tumor control and induces abscopal responses in a humanized mouse model
Morgane M Cogels, Matteo Serra, Hugues Duvillier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2023
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00
Andrea Joaquin Garcia, Mattia Rediti, David Venet, et al.
Ebiomedicine
|
June 9, 2020
Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome
David Venet, Danai Fimereli, Françoise Rothé, et al.
Nature Communications
|
November 29, 2024
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial
Mattia Rediti, David Venet, Andrea Joaquin Garcia, et al.
NPJ Breast Cancer
|
September 22, 2021
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
Andrea Gombos, David Venet, Lieveke Ameye, et al.
JCO Precision Oncology
|
September 28, 2022
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse
Frédéric Cailleux, Elisa Agostinetto, Matteo Lambertini, et al.
Iscience
|
August 18, 2025
Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00
Andrea Joaquin Garcia, Takashi Semba, Mattia Rediti, et al.
Journal of the National Cancer Institute
|
May 23, 2018
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
Michail Ignatiadis, Gert Van den Eynden, Salgado Roberto, et al.
BMC Medicine
|
August 4, 2015
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
Amir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2024
Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Mattia Rediti, Danai Fimereli, Magdalena Mileva, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 48) with videos related to
Sort By:
Page
of 5
Frontiers in Immunology
|
March 27, 2026
Immuno-radiotherapy enhances tumor control and induces abscopal responses in a humanized mouse model
Morgane M Cogels, Matteo Serra, Hugues Duvillier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2023
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00
Andrea Joaquin Garcia, Mattia Rediti, David Venet, et al.
Ebiomedicine
|
June 9, 2020
Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome
David Venet, Danai Fimereli, Françoise Rothé, et al.
Nature Communications
|
November 29, 2024
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial
Mattia Rediti, David Venet, Andrea Joaquin Garcia, et al.
NPJ Breast Cancer
|
September 22, 2021
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
Andrea Gombos, David Venet, Lieveke Ameye, et al.
JCO Precision Oncology
|
September 28, 2022
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse
Frédéric Cailleux, Elisa Agostinetto, Matteo Lambertini, et al.
Iscience
|
August 18, 2025
Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00
Andrea Joaquin Garcia, Takashi Semba, Mattia Rediti, et al.
Journal of the National Cancer Institute
|
May 23, 2018
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
Michail Ignatiadis, Gert Van den Eynden, Salgado Roberto, et al.
BMC Medicine
|
August 4, 2015
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
Amir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2024
Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Mattia Rediti, Danai Fimereli, Magdalena Mileva, et al.
Page
of 5